Post by Galderma

We announced our Q1 performance today, demonstrating outstanding growth of 25.5% year-on-year at constant currency. Among the key factors driving this growth were strong commercial performance across our portfolio, the continued ramp-up of our novel biologic, and the launch of new science-based innovations. At major medical conferences, we advanced our scientific leadership in areas with emerging patient needs. This included presenting pioneering new research on menopause-related skin changes – an often underrecognized patient group. We’re on track to accelerate our growth with confidence in the rest of 2026, as we move closer to becoming the world’s undisputed dermatology powerhouse. Read more about Galderma’s Q1 2026 performance here: https://lnkd.in/eX9TrXfy #AdvancingDermatology #Q1results #GALD

Video Content